Neurelis Unveils Findings on Pediatric Seizure Clusters at Major Neurology Conference

Neurelis to Showcase Key Findings on Pediatric Seizure Treatment

Neurelis, Inc., a leading neuroscience company, is set to present groundbreaking analyses concerning seizure treatment in pediatric patients at the 55th Child Neurology Society Annual Meeting, taking place from October 14 to 17, 2026, in the vibrant city of Montréal, Québec, Canada. This event aims to deepen discussions within the child neurology community about advances in epilepsy treatments and the pressing need for innovative approaches to care for affected pediatric populations.

Highlights of the Presentations

Neurelis’ contributions to this year's gathering will consist of three informative poster presentations, each focusing on separate but interlinked aspects of immediate-use seizure medications in children experiencing seizure clusters.

1. Evaluating Diazepam Nasal Spray in Pediatric Patients: One presentation will encapsulate pooled findings from two studies that assess the effectiveness of diazepam nasal spray in treating early tonic-clonic status epilepticus (SE) episodes in young patients aged between 2 to 17. The analysis reveals that diazepam nasal spray can effectively terminate SE episodes within critical timeframes, exhibiting a median time to administration of only 10 minutes and achieving a rapid median termination time of 5 minutes.

The results indicate that 73.3% of SE episodes were terminated before reaching 30 minutes post-administration, affirming the medication's efficacy during critical moments of treatment.

2. Measuring SEIVAL in Treated Children: Another poster will introduce a novel metric known as SEIVAL (SEIzure interVAL), which assesses the intervals between treated seizure episodes in two separate age groups of children. Findings from this research indicate a significant increase in the mean SEIVAL duration over time, suggesting potential long-term benefits of diazepam nasal spray in preventing subsequent seizures.

For the youngest cohort (aged 2-5 years), the mean SEIVAL duration doubled from 24.4 days in earlier treatment periods to 49.4 days in later periods. Similarly, in older children (aged 6-17 years), the mean interval improved from 15.2 to 28.8 days, reflecting a promising trend in managing the frequency of seizure clusters.

3. Analyzing Seizure Clusters: The third presentation will deliver a detailed examination of seizure clusters derived from a comprehensive clinical dataset compiled from the Comprehensive Children's Epilepsy Centre at Alberta Children's Hospital. Of the analyzed population, 327 patients met criteria for seizure clusters with genetic/metabolic causes reported as prevalent among cases. Insights from this dataset will provide invaluable resources to further research in pediatric epilepsy management and immediate-use medications for seizure rescue.

Expert Commentary

Dr. Adrian L. Rabinowicz, Chief Medical Officer at Neurelis, expressed enthusiasm about participating in the annual meeting, emphasizing the organization's dedication to addressing the unmet medical needs of children with epilepsy. "This meeting presents a significant opportunity to share our findings with fellow neurologists and researchers who share our commitment to improving patient care and outcomes for those grappling with epilepsy's challenges," he remarked.

Importance of the Event

The Child Neurology Society Annual Meeting is an essential platform for healthcare professionals specializing in childhood neurological disorders. It not only promotes sharing of contemporary research findings but also fosters collaboration and exchange of experiences to enhance the quality of care in epilepsy treatments. Neurelis’s presentations will take center stage on October 15 during two dedicated poster sessions, marking a highlight for attendees eager to learn about advancements in pediatric epilepsy management.

About Neurelis, Inc.

Neurelis, Inc. leads the field in developing therapies specifically aimed at treating epilepsy and related neurological disorders characterized by significant unmet needs. Its flagship product, VALTOCO® (diazepam nasal spray), has received FDA approval for the acute treatment of frequent seizure activity in both adults and pediatric patients aged 2 years or older. Neurelis continues its commitment to research by exploring additional therapeutic avenues within the neurological domain, including innovative treatments for schizophrenia and rare CNS disorders.

For comprehensive details on VALTOCO and other developments, please refer to Neurelis's website and stay updated on their ongoing contributions to neuroscience.